Which FDA-approved telehealth platforms prescribe tirzepatide?

1. Which telehealth platforms explicitly market FDA‑approved tirzepatide prescriptions

Manufacturer‑backed LillyDirect directly markets Zepbound with an integrated telehealth pathway and home delivery of authentic Lilly medicines, positioning it as an official channel for the FDA‑approved product ^{[1] [2]}, and mainstream telemedicine weight‑clinic programs such as Sesame Care and WeightWatchers’ clinic pages say their clinicians may prescribe Zepbound or Mounjaro when medically appropriate via virtual visits ^{[3] [6]}. CallOnDoc and Heally are named in provider material as telehealth services that state they will prescribe Zepbound after a virtual evaluation and arrange pharmacy delivery ^{[4] [5]}.

2. The distinction between FDA‑approved brands and compounded alternatives

A recurring theme across reviews and vendor pages is that some telehealth platforms offer both FDA‑approved branded tirzepatide and compounded formulations; vaccinealliance and other clinic reviews warn platforms disclose whether they use Zepbound/Mounjaro or compounded tirzepatide, because compounded products are not FDA‑approved and may vary by state and pharmacy ^{[7] [8]}. Independent aggregator and review sites list telehealth providers that prescribe brand‑name tirzepatide and others that rely on compounded alternatives to offer lower prices, underscoring a marketplace split between authentic manufacturer supply and cheaper compounded options ^{[7] [9]}.

3. Regulatory context matters for which telehealth platforms can safely prescribe

Regulatory shifts have narrowed the legitimate routes for non‑brand tirzepatide: the FDA ended broad enforcement discretion for compounded tirzepatide in March 2025, meaning most compounding is no longer legally permissible absent documented medical necessity, a development telehealth prescribers and patients must factor into sourcing decisions ^[10]. Industry summaries and press briefings note that some telehealth platforms continue to advertise compounded tirzepatide programs, but these offerings carry regulatory and quality caveats that differ from manufacturer supply chains like LillyDirect ^{[11] [9]}.

4. How commercial incentives and transparency shape what platforms emphasize

Several platforms and review sites prioritize price, convenience, and subscription models — which can create incentives to promote compounded options or proprietary fulfillment partnerships — while manufacturer channels emphasize authenticity and pharmacy verification; vaccinealliance’s reviews flagged transparency about sourcing and pricing as a key trust metric, and GLP‑1 focused sites likewise rank platforms by whether they disclose brand vs compounded sourcing ^{[7] [9]}. That creates a potential hidden agenda: lower‑cost telehealth offerings may lean on compounded supply chains to undercut brand prices, even as manufacturer or insurer channels stress FDA approval and established safety profiles ^{[9] [8]}.

5. Practical takeaway for patients navigating telehealth prescriptions

The reporting supports a practical rule: platforms that explicitly name Zepbound or Mounjaro and tie fulfillment to known manufacturer or accredited pharmacy channels — LillyDirect, Sesame Care, WeightWatchers’ clinic, Heally, and CallOnDoc are among those cited — are advertising that they will prescribe FDA‑approved tirzepatide after clinical evaluation, whereas other vendors may mix or prefer compounded tirzepatide for cost reasons and face different regulatory scrutiny ^{[1] [2] [3] [6] [5] [4] [9] [8] [10]}. The existing sources do not provide a comprehensive, up‑to‑the‑minute registry of every telehealth provider that prescribes the branded drugs, so verification with each platform about whether prescriptions are for FDA‑approved Zepbound/Mounjaro (and how the drug will be fulfilled) remains essential before assuming a prescription will be filled with an FDA‑approved product ^{[7] [10]}.